Drugs / EBV specific T cells
EBV specific T cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00082225 | Oct 2003 → Feb 2006 | lymphoma | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00058812 | May 1993 → Jul 2014 | Epstein-Barr virus infection | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03988582 | Jun 2019 → Jun 2020 | Epstein-Barr virus-related tumor, lymphoma | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT06391814 | Jan 2024 → Apr 2025 | EBV-positive T-cell lymphoproliferative disorder of childhood | Ciusss de L'Est de l'Île de Montréal | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00082225 ↗ |
| Known as | EBV-CTLs | “treatment with EBV-specific cytotoxic T cells (EBV-CTLs) is effective” NCT03988582 ↗ |
| Known as | EBV-specific cytotoxic T cells | “treatment with EBV-specific cytotoxic T cells (EBV-CTLs) is effective” NCT03988582 ↗ |
| Action | Deplete | “These cells have been trained to attack EB virus infected cells.” NCT00058812 ↗ |
| Modality | Cell therapy | “special immune system cells called LMP2 specific cytotoxic T lymphocytes” NCT00082225 ↗ |
| Route | Intravenous | “injected through an intravenous line” NCT00058812 ↗ |